• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characteristics of Hospitalized Elderly Patients with Severe Pneumonia Due to SARS-CoV-2, Vaccinated Against COVID-19.感染新型冠状病毒且接种过新冠疫苗的老年重症肺炎住院患者的特征
Life (Basel). 2025 May 29;15(6):879. doi: 10.3390/life15060879.
2
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
3
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
6
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
7
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
8
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。
Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.
9
Remdesivir for the treatment of COVID-19.瑞德西韦治疗 COVID-19。
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
10
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.

本文引用的文献

1
Covid-19: WHO declares end of global health emergency.新冠疫情:世界卫生组织宣布全球卫生紧急状态结束。
BMJ. 2023 May 9;381:1041. doi: 10.1136/bmj.p1041.
2
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.新冠疫苗的真实世界有效性:文献综述和荟萃分析。
Int J Infect Dis. 2022 Jan;114:252-260. doi: 10.1016/j.ijid.2021.11.009. Epub 2021 Nov 17.
3
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
4
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.肾移植受者和透析患者对 SARS-CoV-2 BNT162b2 疫苗的体液免疫受损。
Sci Immunol. 2021 Jun 15;6(60). doi: 10.1126/sciimmunol.abj1031.
5
Effective public health measures to mitigate the spread of COVID-19: a systematic review.有效控制 COVID-19 传播的公共卫生措施:系统综述。
BMC Public Health. 2021 May 29;21(1):1015. doi: 10.1186/s12889-021-11111-1.
6
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后,mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果:一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
7
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
8
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
9
Why does COVID-19 disproportionately affect older people?为什么新冠病毒对老年人的影响尤为严重?
Aging (Albany NY). 2020 May 29;12(10):9959-9981. doi: 10.18632/aging.103344.

感染新型冠状病毒且接种过新冠疫苗的老年重症肺炎住院患者的特征

Characteristics of Hospitalized Elderly Patients with Severe Pneumonia Due to SARS-CoV-2, Vaccinated Against COVID-19.

作者信息

Kisiel Jakub, Chojnicki Michał, Kowala-Piaskowska Arleta, Wieczorowska-Tobis Katarzyna, Tobis Sławomir, Religioni Urszula, Merks Piotr, Neumann-Podczaska Agnieszka

机构信息

Multispecialist Municipal Hospital, J. Struś Memorial Hospital, Szwajcarska 3, 61-285 Poznan, Poland.

Department of Medical Biology, Poznan University of Medical Sciences, Rokietnicka 10, 60-806 Poznan, Poland.

出版信息

Life (Basel). 2025 May 29;15(6):879. doi: 10.3390/life15060879.

DOI:10.3390/life15060879
PMID:40566535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12194051/
Abstract

The introduction of COVID-19 vaccinations has significantly altered the course of the pandemic by markedly reducing the number of severe infection cases, hospitalizations, and deaths due to COVID-19. Elderly individuals constitute a particularly vulnerable group at risk of severe disease progression, which is often related to decreased immune system effectiveness and comorbidities. Severe infection outcomes in vaccinated individuals, though substantially rarer than in the unimmunized population, can still lead to death due to underlying health conditions. This analysis aims to describe the population of elderly individuals who, despite being vaccinated, died from interstitial pneumonia complicating SARS-CoV-2 infection. Data on the infection course and co-existing diseases were obtained from the database of the Józef Struś Multispecialty City Hospital in Poznań, which was converted into a dedicated facility during the pandemic. The inclusion criteria for the analysis were being over 60 years of age on the day of hospital admission, confirmed pneumonia in radiological examination, COVID-19 infection confirmed by PCR test, and an adverse disease course resulting in death. Patients admitted to the hospital from 1 June 2021 to 31 December 2021 were analyzed. Out of all hospitalizations, only 18 individuals met the inclusion criteria. Given the small number of patients, the authors employed descriptive methods to illustrate the clinical states of the individual patients, presenting SARS-CoV-2 infection in the context of co-existing diseases that significantly affect prognosis. The qualitative analysis employed highlights the complex and multidimensional courses of severely ill COVID-19 patients more emphatically.

摘要

新冠疫苗的引入显著改变了疫情的发展进程,通过大幅减少新冠导致的严重感染病例、住院人数和死亡人数。老年人是特别脆弱的群体,有患重症疾病进展的风险,这通常与免疫系统有效性下降和合并症有关。接种疫苗的个体中出现严重感染后果的情况虽然比未接种疫苗的人群罕见得多,但仍可能因基础健康状况而导致死亡。本分析旨在描述尽管接种了疫苗,但仍死于合并新型冠状病毒感染的间质性肺炎的老年人群体。感染过程和并存疾病的数据来自波兹南约瑟夫·斯特鲁斯多专科医院的数据库,该医院在疫情期间被改造成了专门的设施。分析的纳入标准为入院当天年龄超过60岁、放射学检查确诊肺炎、PCR检测确诊新冠病毒感染以及病情恶化导致死亡。对2021年6月1日至2021年12月31日期间入院的患者进行了分析。在所有住院患者中,只有18人符合纳入标准。鉴于患者数量较少,作者采用描述性方法来说明个体患者的临床状态,在显著影响预后的并存疾病背景下呈现新型冠状病毒感染情况。所采用的定性分析更着重地突出了重症新冠患者复杂和多维度的病程。